healthcare professional> why cardiolite®> risk stratification

An MPI With Cardiolite® Gives You the Information to Help Manage Your Patients With Confidence

*Based on a prospective study of 5807 patients, designed to determine the incremental prognostic value of SPECT for the prediction of cardiac death and the implications for risk stratification in patients undergoing dual-isotope SPECT with either exercise or pharmacological stress and followed for 642 ± 226 days, with prognostic data available for 5183 patients.5

‡Statistically significant (P<0.05) increase in rate of MI versus cardiac death within scan category5

§Statistically significant (P<0.001) increase as a scan result5

Adapted from Hachamovitch R et al.5

The Signs May Be There in Your Patients With Diabetes and Known or Suspected CAD§

§The indications for Cardiolite® are not specific to patients with diabetes. Cardiolite® was shown to be an effective prognostic tool in the evaluation of patients with known or suspected CAD. This was determined in 3 pivotal trials enrolling 1596 patients, including 311 patients with diabetes, which were used as the basis for approval.

||Statistically significant (P<0.001) increase in event rates as a function of summed stress score12

Adapted from Kang X et al.12

In patients with diabetes, and with stable CAD and a normal Cardiolite® scan, data iindicate a 1–2% risk of cardiac death or MI in the following year12¶#

¶Based on a prospective study of 1271 patients with diabetes and 5862 patients without diabetes with known or suspected CAD designed to evaluate the incremental value of stress myocardial perfusion SPECT in patients with diabetes.12

#A second prospective study of 929 patients with diabetes and 3826 patients without diabetes with symptoms of CAD. 4755 patients were followed for 2.5 (+1.5) years for subsequent occurrence of cardiac death, MI, or revascularization.  A separate survival analysis was performed comparing patients with and without diabetes who had normal stress MPI images. For the first 2 years of the study follow-up, patients with normal stress MPI images had similar survival curves, irrespective of their diabetic status.13

Rely on the Information of an MPI With Cardiolite® for Confident Risk Stratification of Your Patients

**Results from a gated MPI with Cardiolite® along with other clinical evaluations and test results should all be considered in making patient management decisions.

Is the predicted cardiac mortality in a nuclear stress test with pharmacologic stress the same in women and men?

††In a study population that consisted of 6173 consecutive patients with known or suspected CAD who underwent dual isotope MPI with pharmacological stress and followed up for 27 ± 8.8 months (4.1% of patients were lost to follow up); the final population included 2677 males and 2656 females.16

Adapted from Berman DS et al.16

†††In a second prospective study of 2377 consecutive patients (1226 men and 1151 women) who underwent exercise or dypyridamole Tc-99m sestamibi SPECT and who were followed up over 15± 8 months where only 2228 patients were available for follow-up; to evalutate gender differences in the use of Tc-99m sestamibi for subsequent referrals for invasive procedures and its prognostic value in predicitng subsequent cardiac events.23

In women and men, a gated nuclear stress test with Cardiolite®:

• Adds incremental value in the prediction of cardiac death16,17

• Provides information that may assist you in making confident patient management decisions5,17–19

 

Indications and Usage:   Cardiolite®, Kit for the Preparation of Technetium Tc99m Sestamibi for Injection, is a myocardial perfusion agent that is indicated for detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects), in evaluating myocardial function and developing information for use in patient management decisions. Cardiolite® evaluation of myocardial ischemia can be accomplished with rest and cardiovascular stress techniques (eg, exercise or pharmacologic stress in accordance with the pharmacologic stress agent's labeling). It is usually not possible to determine the age of a myocardial infarction or to differentiate a recent myocardial infarction from ischemia. Important Safety Information: Exercise and pharmacologic stress testing should be performed only under the supervision of a qualified physician. Cardiolite® has been rarely associated with acute severe allergic events of angioedema and urticaria. The most frequently reported adverse events include headache, chest pain/angina, ST segment changes on ECG, nausea, and abnormal taste and smell. Please See Full Prescribing Information